New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSLU-PP-332 vs Decapeptide-12

SLU-PP-332 vs Decapeptide-12

Side-by-side comparison of key properties, dosing, and research.

Recovery & RepairFat Loss & Metabolic
SLU-PP-332
Skin & Cosmetic
Decapeptide-12
Summary
SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
Decapeptide-12 is a synthetic 10-amino acid peptide developed for skin brightening and depigmentation. It selectively inhibits tyrosinase activity and downstream melanogenesis pathways, reducing hyperpigmentation, dark spots, and uneven skin tone without the irritation associated with hydroquinone.
Half-Life
Not established in humans; rodent pharmacokinetics suggest hours
Not applicable (topical)
Admin Route
Oral (research), Subcutaneous (research)
Topical
Research
Typical Dose
Not established for humans; rodent studies used ~100 mg/kg/day
5 ppm (0.0005%) concentration
Frequency
Once daily in rodent studies
Twice daily (AM and PM)
Key Benefits
  • Significant enhancement of aerobic endurance capacity
  • Increases mitochondrial density and oxidative metabolism in muscle
  • Promotes beneficial shift toward oxidative muscle fiber phenotype
  • Improves cardiac efficiency and cardiovascular fitness markers
  • Potential for obesity, metabolic syndrome, and heart failure treatment
  • Exercise mimetic for populations unable to exercise (disability, frailty, disease)
  • Reduces hyperpigmentation and dark spots
  • Evens skin tone and improves radiance
  • Inhibits post-inflammatory hyperpigmentation
  • Well-tolerated alternative to hydroquinone
  • Effective for melasma and age spots
  • Non-cytotoxic to melanocytes
Side Effects
  • Limited human data; all studies are preclinical (rodent)
  • Unknown cardiovascular effects with long-term or high-dose use in humans
  • Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
  • Off-target effects not fully characterized
  • Generally very well-tolerated
  • Rare mild irritation or sensitivity in some skin types
  • Results may take several weeks to become visible
Stacks With